Dear All: As we head into the Easter and Passover weekend, three new calls for proposals have emerged! Perhaps one of these is for you?
- The US CDC has released a Broad Agency Announcement (FY2018-OADS-BAA) seeking proposals for projects across a range of areas (diagnostics, transmission, microbiome disruption, resistance genes in the environment, and stewardship). Initial proposals are due 16 April 2018.
- Via Innovate UK, the UK Department of Health and Social Care (DHSC) and The Chinese Ministry of Science and Technology (MOST) have announced a competition in which collaborations between UK- and China-based partners can access £10 million (UK) and 60 million Renminbi (China). The topics of interest include Chinese medicines, new agents, improved used of existing agents, and diagnostics. The competition window is 3 April 2018 to 6 June 2018.
- The Wellcome Trust is opening a Request for Proposals for an evaluation of the likelihood of successful development and implementation for vaccines against pathogens with high levels of antimicrobial resistance, including a survey of the product development landscape and market analysis. The evaluation will identify barriers to the development and implementation for these vaccines and provide recommendations on the development of these vaccines. See this link for more details. Proposals are due 16 April 2018.
For the first two, see below my signature for a bit more detail. All best wishes, –jr
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/
CDC’s list of areas: 6 categories spanning 35 AMR-focused topics. Go to this link for the full announcement.
- New diagnostic, sequencing, and metagenomic tools for AR detection and improved antibiotic use
- International transmission, colonization, and prevention of AR pathogens
- Domestic transmission, colonization, and prevention of AR pathogens and C. difficile infections
- Develop human microbiome disruption indices relevant to AR
- Resistant pathogens and genes in water systems and the environment and their contribution to human infections
- Improving antibiotic stewardship
Innovate UK – DHSC – MOST areas of interest: Go to this link for the full announcement
- explore opportunities from traditional Chinese medicine for the treatment or prevention of infectious bacterial diseases in humans or animals
- advance the discovery of new agents to prevent or treat drug-resistant bacterial infection in humans or livestock. New agents could include small molecule drugs, vaccines, antibodies or other biological products
- identify new agents that will increase the feed energy conversion in livestock. This should be done without use of antibiotics or hormones
- use modelling and prospective and retrospective clinical studies to maximise the clinical utility of current antibiotics. Focus especially on those against drug-resistant Gram-negative bacteria. Projects must aim to improve the prognosis of patients with extensively drug-resistant infections
- improve capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistance
Upcoming meetings of interest to the AMR community:
- 16 Apr 2018 (Washington): Duke-Margolis & FDA event: “Evaluating Inclusion and Exclusion Criteria in Clinical Trials”
- 21-24 Apr 2018 (Madrid): ECCMID
- 4-7 Jun 2018 (Boston): BIO (multiple AMR-focused sessions are expected)
- 7-11 Jun 2018 (Atlanta): ASM Microbe
- 22-27 Jul 2018 (Bryant University, Smithfield, RI): Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture
- 4-7 Sep 2018 ESCMID-ASM Conference (#3) on Drug Development for AMR (Lisbon, Portugal)
- 6-14 Oct 2018 International Course on Antibiotics and Resistance (ICARe, Les Pensières, Annecy, France)